Information Provided By: 
Fly News Breaks for April 16, 2018
ICPT
Apr 16, 2018 | 08:29 EDT
At "only" a $1.8B market capitalization following the pullback over the past year, shares of Intercept Pharmaceuticals are "undervalued," Jefferies analyst Michael Yee tells investors in a research note after hosting investor meetings with management. The analyst sees the stock "climbing back higher" as U.S. Ocaliva scripts stabilize and the 2019 Phase 3 data release in nonalcoholic steatohepatitis gets closer. The analyst expects the data to be positive. He keeps a Buy rating on Intercept with a $135 price target.
News For ICPT From the Last 2 Days
There are no results for your query ICPT
